Shares of UCB SA (OTCMKTS:UCBJF) shot up 1.9% during mid-day trading on Wednesday . The company traded as high as $96.43 and last traded at $96.43. 250 shares were traded during mid-day trading, a decline of 14% from the average session volume of 290 shares. The stock had previously closed at $94.63.
Separately, Zacks Investment Research cut shares of UCB from a “hold” rating to a “sell” rating in a research note on Saturday, February 20th.
The company’s fifty day moving average price is $98.99 and its two-hundred day moving average price is $106.74. The firm has a market cap of $18.76 billion, a P/E ratio of 16.57 and a beta of 0.56.
UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases in the United States, Europe, and internationally. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; and Nayzilam, a nasal spray rescue treatment for seizure clusters.
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.